# Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

> **NCT01035879** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 100 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** MBX-2982
- **DRUG:** MBX-2982
- **DRUG:** MBX-2982
- **DRUG:** Sitagliptin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01035879
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035879, "Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01035879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*